Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Prothena Corporation (PRTA) shares have plunged 40% year-to-date following significant pipeline setbacks, notably the discontinuation of its wholly-owned birtamimab program and high ARIA-E rates observed in its PRX012 Alzheimer's candidate, which now seeks partnership for advancement. Despite these challenges, the company maintains future revenue potential through advancing partnered assets: Novo Nordisk is progressing coramitug into Phase III for ATTR amyloidosis in 2025, offering up to $1.2 billion in milestones, and Roche plans Phase III initiation for prasinezumab in Parkinson's disease by year-end 2025, promising double-digit royalties. These advancements in partnered programs offer a counterbalance to the recent failures in its proprietary pipeline.

Analysis

Prothena's stock has plummeted 40% year-to-date, starkly underperforming the industry's 6.6% gain, driven by critical setbacks in its proprietary drug pipeline. The company discontinued development of its wholly-owned candidate, birtamimab, following a late-stage trial failure, which prompted a significant 63% workforce reduction to streamline costs. Furthermore, its Alzheimer's candidate, PRX012, demonstrated a concerning safety profile with higher-than-expected ARIA-E rates, despite showing effective amyloid plaque reduction. This has clouded its independent development path and forced the company to seek a partnership. The investment thesis for Prothena now pivots almost entirely to its de-risked, partnered programs. Positive momentum stems from decisions by major pharmaceutical partners to advance assets into late-stage trials; Novo Nordisk is progressing coramitug into a Phase III program in 2025, which carries up to $1.2 billion in potential milestone payments for Prothena, while Roche is advancing prasinezumab into Phase III, entitling Prothena to double-digit teen royalties on future sales. This creates a bifurcated outlook where the company's ability to independently develop assets is severely challenged, but its value is now primarily underpinned by the clinical and commercial execution of its large-cap partners.

Key Decisions for Investors

• Investors should re-evaluate Prothena's valuation based on a sum-of-the-parts analysis of its future milestone and royalty streams from partners, as the investment thesis has shifted away from its challenged proprietary pipeline.
• Closely monitor key catalysts in 2025, specifically the Phase III trial initiations for coramitug by Novo Nordisk and prasinezumab by Roche, as these events are directly tied to near-term payments and long-term value.
• Acknowledge the heightened dependency risk, as Prothena's success is now largely contingent on its partners' clinical outcomes, and consider any potential partnership for the troubled PRX012 candidate as a speculative catalyst.